Chronic imipramine downregulates cyclic AMP signaling in rat hippocampus

NeuroReport

Volumn 20, Issue 3, 2009, Pages 307-311

  Reierson, Gillian W ^a   Mastronardi, Claudio A ^a   Licinio, Julio ^a   Wong, Ma Li ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Antidepressant; Cyclic; Hippocampus; Nucleotides, phosphodiesterase; Rat

Indexed keywords

ADENYLATE CYCLASE; ADENYLATE CYCLASE 1; BRAIN DERIVED NEUROTROPHIC FACTOR; CYCLIC AMP; CYCLIC GMP; GUANYLATE CYCLASE; GUANYLATE CYCLASE ALPHA2; GUANYLATE CYCLASE BETA1; IMIPRAMINE; PHOSPHODIESTERASE; PHOSPHODIESTERASE 3A; PHOSPHODIESTERASE 3B; PHOSPHODIESTERASE 5A; PHOSPHODIESTERASE IV; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DEGRADATION; DOWN REGULATION; DRUG MECHANISM; ENZYME IMMUNOASSAY; GENE EXPRESSION; HIPPOCAMPUS; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; SYNTHESIS;

ADENYLATE CYCLASE; ANIMALS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; BRAIN-DERIVED NEUROTROPHIC FACTOR; CYCLIC AMP; CYCLIC GMP; DEPRESSIVE DISORDER; DOWN-REGULATION; DRUG ADMINISTRATION SCHEDULE; HIPPOCAMPUS; IMIPRAMINE; MALE; PHOSPHORIC DIESTER HYDROLASES; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER;

EID: 62149117324     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNR.0b013e328321b5a0     Document Type: Article

References (23)

1. Halene TB, Siegel SJ. PDE inhibitors in psychiatry-future options for dementia, depression and schizophrenia? Drug Discov Today 2007; 12:870-878.
2. Nair A, Vaidya VA. Cyclic AMP response element binding protein and brain- derived neurotrophic factor: molecules that modulate our mood? J Biosci 2006; 31:423-434.
3. Tanis KQ, Duman RS. Intracellular signaling pathways pave roads to recovery for mood disorders. Ann Med 2007; 39:531-544.
4. Matsuoka I, Suzuki Y, Defer N, Nakanishi H, Hanoune J. Differential expression of type I, II, and V adenylyl cyclase gene in the postnatal developing rat brain. J Neurochem 1997; 68:498-506.
5. Mergia E, Russwurm M, Zoidl G, Koesling D. Major occurrence of the new alpha2beta1 isoform of NO-sensitive guanylyl cyclase in brain. Cell Signal 2003; 15:189-195.
6. Hebb AL, Robertson HA. Role of phosphodiesterases in neurological and psychiatric disease. Curr Opin Pharmacol 2007; 7:86-92.
7. Bender AT, Beavo JA. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 2006; 58:488-520.
8. Menniti FS, Faraci WS, Schmidt CJ. Phosphodiesterases in the CNS: targets for drug development. Nat Rev Drug Discov 2006; 5:660-670.
9. Nibuya M, Nestler EJ, Duman RS. Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. J Neurosci 1996; 16:2365-2372.
10. Takahashi M, Terwilliger R, Lane C, Mezes PS, Conti M, Duman RS. Chronic antidepressant administration increases the expression of cAMP-specific phosphodiesterase 4A and 4B isofomns. J Neurosci 1999; 19:610-618.
11. D'Sa C, Eisch AJ, Boiger GB, Duman RS. Differential expression and regulation of the oAMP-selective phosphodiesterase type 4A splice variants in rat brain by chronic antidepressant administration. The Eur J Neurosc 2005; 22:1463-1475.
12. Suda S, Nibuya M, Ishiguro T, Suda H. Transcriptional and translational regulation of phosphodiesterase type IV isozymes in rat brain by electroconvulsive seizure and antidepressant drug treatment. J Neurochem 1998; 71:1554-1563.
13. Ye Y, Jackson K, O'Donnell JM. Effects of repeated antidepressant treatment of type 4A phosphodiesterase (PDE4A) in rat brain. J Neurochem 2000; 74:1257-1262.
14. Miro X, Perez-Torres S, Artigas F, Puigdomenech P, Palacios JM, Mengod G. Regulation of cAMP phosphodiesterase mRNAs expression in rat brain by acute and chronic fluoxetine treatment. An in situ hybridization study. Neuropharmacology 2002; 43:1148-1157.
15. Dlaboga D, Hajjhussein H, O'Donnell JM. Regulation of phosphodiesterase- 4 (PDE4) expression in mouse brain by repeated antidepressant treatment: comparison with rolipram. Brain Res 2006; 1096:104-112.
16. Cho CH, Cho DH, Seo MR, Juhnn YS. Differential changes in the expression of cyclic nucleotide phosphodiesterase isoforms in rat brains by chronic treatment with electroconvulsive shock. Exp Mol Med 2000; 32:110-114.
17. Brady LS, Whitfield HJ Jr, Fox RJ, Gold PW, Herkenham M. Long-term antidepressant administration alters corticotropin-releasing hormone, tyrosine hydroxylase, and mineralocorticoid receptor gene expression in rat brain. Therapeutic implications. J Clin Invest 1991; 87:831-837.
18. Brady LS, Gold PW, Herkenham M, Lynn AB, Whitfield HJ Jr. The antidepressants fluoxetine, idazoxan and phenelzine alter corticotropin- releasing hormone and tyrosine hydroxylase mRNA levels in rat brain: therapeutic implications. Brain Res 1992; 572:117-125.
19. Wang H, Edens NK. mRNA expression and antilipolytic role of phosphodiesterase 4 in rat adipocytes in vitro. J Lipid Res 2007; 48:1099-1107.
20. Altar CA, Whitehead RE, Chen R, Wortwein G, Madsen TM. Effects of electroconvulsive seizures and antidepressant drugs on brain-derived neurotrophic factor protein in rat brain. Biological psychiatry 2003; 54:703-709.
21. Jacobsen JP, Mork A. The effect of escitalopram, desipramine, electroconvulsive seizures and lithium on brain-derived neurotrophic factor mRNA and protein expression in the rat brain and the correlation to 5-HT and 5-HIAA levels. Brain Res 2004; 1024:183-192.
22. De Foubert G, Carney SL, Robinson CS, Destexhe EJ, Tomlinson R, Hicks CA, et al. Fluoxetine-induced change in rat brain expression of brain-derived neurotrophic factor varies depending on length of treatment. Neuroscience 2004; 128:597-604.
23. Balu DT, Hoshaw BA, Malberg JE, Rosenzweig-Lipson S, Schechter LE, Lucki I. Differential regulation of central BDNF protein levels by antidepressant and non-antidepressant drug treatments. Brain Res 2008; 1211:37-43.